Focal Therapy in Localized Prostate Cancer

What is it?

Focal therapy is a growing minimally invasive treatment option for patients with low to intermediate risk prostate cancer that is completely contained (localized) within the prostate. An estimated 1.2 million patients are diagnosed with localized prostate cancer each year in the world (source: WHO Global Cancer Observatory ( Focal therapy could offer them significant improvements over today’s standard of care.

Today’s Standard of Care for Prostate Cancer Treatment

Two main approaches to managing localized prostate cancer are today considered as standard of care. The first is the so called “active surveillance”. In these cases, regular tests are performed to monitor the development or progression of the cancer. As long as the cancer is stable, no other actions are taken. If the cancer is starting to spread, treatment will be offered. Of those patients on active surveillance, about one-third will eventually need treatment. Being on active surveillance has shown to be mentally stressful for some patients.

The second approach to managing localized prostate cancer is the use of radiation or surgery. This is effective for removing any tumors present but is typically associated with unpleasant side effects influencing quality of life, such as loss of control over urinary functions (incontinence) and erectile dysfunction.

Focal Therapy offers potentially significant advantages over Standard of Care

Focal therapy is a minimally invasive treatment that targets and ablates (destroys) only specific parts of glands, organs, and tissue needing treatment, while preserving the surrounding and remaining tissue.  This generally produces faster recovery, fewer side effects, and less pain and discomfort for patients that may not be good candidates or are inoperable for traditional open surgery.

Focal therapy offers to preserve these vital functions while still treating the cancer effectively. Focal therapy concentrates on treating “the index lesion,” which is usually defined as a tumor visible on MRI. By precisely targeting and destroying index lesions with focal therapy, the cancer tumor can be effectively treated while preserving surrounding tissue and minimizing side effects.

In a European Urology consensus meeting, it was agreed, with a high level of consensus, that focal therapy should be recommended for intermediate-risk patients (ref: Donaldson et al, 2015).

Laser Ablation in Prostate Focal Therapy

TRANBERG Thermal Therapy System is used to provide laser focal therapy of localized prostate cancer. The procedure is minimally invasive and can be performed at a urology clinic or radiology department. Side effects are minimal and typically the patient can return quickly to normal life. 

Image and needle guidance is used for navigating and positioning the sterile introducer and laser applicator at the correct location in the target tissue, using either the transrectal or transperineal access path. The TRANBERG system can be seamlessly integrated with an existing ultrasound fusion system in conjunction with a (stereotactic) needle guide system and a workflow very similar to that used for targeted biopsies. Our solutions for real-time monitoring and control of the procedure enable the physician to personalize and optimize the treatment for each patient.

Animation showing Fusion-guided Focal Laser Ablation – A detailed video animation of the minimally invasive, fusion-guided, focal laser ablation (FLA) of a prostate tumor using the 510(k) cleared TRANBERG™ Thermal Therapy System.


Patient Focused

  • Minimally invasive procedure allowing the patient to quickly return to normal life(1).
  • Short procedure time and low pain (2, 5).
  • Low risk of complications including erectile dysfunction and urinary incontinence(3, 5).
  • Low risk of infections (3).
1. Fütterer et al. World J Urol. (2019)
2. Marks et al. J Urol. (2017)
3. Klotz et al. Curr Opin Urol. (2020)


  • Precise positioning of the laser applicator in the defined target area using MRI-US fusion for image-guidance.
  • Option to choose between transperineal and transrectal pathway access (4).
  • Sharp ablation zone (1).
  • Surrounding, non-cancerous tissue is spared (3).
4. Williams et al. J Vasc Interv Radiol. (2019)
5. Oddens et al. Eur Urol Open Sci. (2022)


News and insights

21 March, 2023

NEW: Animation showing Fusion-guided Focal Laser Ablation in Prostate Cancer

We are proud to release a detailed video animation of the minimally invasive, fusion-guided, focal laser ablation (FLA) of a prostate tumor using the TRANBERG™ Thermal Therapy System.

Read more
21 March, 2023

Post-Market Study to Evaluate CLS’s TRANBERG Thermal Therapy System by HALO Dx

We are happy to share that HALO Diagnostics, Inc. (HALO Dx) will evaluate the safety and short term efficacy of CLS’s TRANBERG® Thermal Therapy System for treating low-to-medium risk prostate cancer patients.

Read more
6 February, 2023

CLS Americas and URN Announce Treatment of 20th & Final Patient in Clinical Study

CLS Americas announces the full twenty patients have been safely treated in the Phase I clinical study titled, “Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

Read more

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!

Please choose your country or region